AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02435680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: taken by I.V
Study NCT02435680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: taken by I.V
Study NCT04683081 — intervention group
Intervention type: DEVICE
Intervention: mechanical cervical ripening
Description: mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
Study NCT01996267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTC+Pertuzumab
Description: Cycle repeated every 21 days
Study NCT01996267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-T+Pertuzumab
Description: Cycle is repeated every 21 days
Study NCT01945645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready to act
Description: The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
Study NCT01309906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational lens
Description: Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
Study NCT01309906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua lens
Description: Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
Study NCT04391595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Study NCT04391595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: 400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Study NCT01688947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 50-mg tablets
Description: Taken orally twice daily
Study NCT01688947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 30-mg tablets
Description: Taken orally twice daily
Study NCT01688947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsules
Description: 1-2 capsules taken orally twice daily
Study NCT01688947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
Study NCT01688947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
Study NCT01688947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
Study NCT02521233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan + Chlorthalidone (8mg+12,5mg)
Study NCT02521233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan + Chlorthalidone (8 mg + 25 mg)
Study NCT02521233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan+hydrochlorothiazide
Study NCT02337283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablets
Study NCT02337283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT00609180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
Study NCT00609180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
Study NCT02448979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left thoracotomy
Description: Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
Study NCT02448979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right thoracotomy
Description: Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
Study NCT01134406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros Joint Therapy
Description: Single intra-articular injection.
Study NCT01134406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros-TA Joint Therapy
Description: Single intra-articular injection
Study NCT01134406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Description: Single intra-articular injection.
Study NCT02912130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: 1.2-1.5g/kg/body weight per day
Study NCT02583399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen, 10 mg/kg
Study NCT02481440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells (hUC-MSCs)
Description: Four times of intrathecal administrations of hUC-MSCs
Study NCT02857205 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fecal samples
Description: High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
Study NCT01637792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three 2-liter exchanges daily CAPD
Description: CAPD regimen of three 2-liter daily exchanges
Study NCT01637792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Four 2-liter exchanges daily CAPD
Description: CAPD regimen of four 2-liter daily exchagnes
Study NCT02912130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 30-60 minutes per week of moderate intensity exercise
Study NCT02912130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minutes per week of progressive resistance training
Study NCT01359761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post Admission Cognitive Therapy (PACT)
Description: Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
Study NCT00596245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT400
Description: MT 400, naproxen sodium 550mg
Study NCT03708484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Interval Training
Description: Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises.
Study NCT03708484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic + Resistive Interval Training
Description: Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises.
Study NCT04264182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICD programming
Description: Re-programming of the ICD device for VA detection (see above)
Study NCT04334044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet
Description: Ruxolitinib 5 mg twice a day
Study NCT03076086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced sputum procedure
Description: induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
Study NCT03846531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nano-Pulse Stimulation (NPS)
Description: The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
Study NCT00361699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Study NCT00673023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary experiments
Description: Dietary Supplement: high PUFA diet followed by high SFA diet
Study NCT04326244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
Study NCT04326244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: genetic test
Description: FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
Study NCT04326244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Constitution in Chinese Medicine Questionnaire
Description: Constitution in Chinese Medicine Questionnaire
Study NCT04326244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Epworth Sleepiness Scale
Description: Epworth Sleepiness Scale
Study NCT04326244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cephalometry
Description: Evaluation of craniofacial morphology in OSA patients
Study NCT04326244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
Study NCT01070563 — intervention group
Intervention type: OTHER
Intervention: Transcranial doppler
Description: A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
Study NCT02539498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HR-pQCT
Description: HR-pQCT to evaluate cortical and trabecular bone
Study NCT02539498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: HR-pQCT to evaluate cortical and trabecular bone
Study NCT00364000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate
Description: Calcium acetate in 240 chronic HD patients
Study NCT00364000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Description: Calcium acetate in 240 chronic HD patients
Study NCT04029389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection
Description: Local corticosteroid injection
Study NCT04029389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial nerve block
Description: Tibial nerve block
Study NCT01757054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProNutrients Probiotic
Description: Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
Study NCT00553150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT02819999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT04029389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservational therapy
Description: Only exercise and foot insoles
Study NCT01666119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Buprenorphine NX films
Description: BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
Study NCT02343094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBA 7,5g/d
Description: Treatment for 14 days with PBA
Study NCT02343094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBA 15g/d
Description: Treatment for 14 days with PBA
Study NCT00553150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00554619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325760A
Description: 2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
Study NCT02088073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Sodium zirconium cyclosilicate
Study NCT02088073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
Study NCT00553150 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Study NCT04229615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib; Apatinib
Description: Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
Study NCT04507451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inspiratory and expiratory muscle training
Description: inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
Study NCT04229615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib Orally twice daily
Study NCT04229615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04507451 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: inspiratory and expiratory exercises
Description: inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
Study NCT00665847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (TMC125)
Description: Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
Study NCT00665847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR)
Description: An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
Study NCT03965533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
Study NCT00899717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Description: modification of occlusal surfaces
Study NCT00899717 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo occlusal adjustment
Description: Simulated modification of occlusal surfaces
Study NCT01427517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Single, intravenous administration of N-acetylcysteine
Study NCT02792491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Description: Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Study NCT03965533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
Study NCT06010940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement
Description: nasogastric tube and oral care
Study NCT06010940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Description: nasogastric tube and oral care
Study NCT06010940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
Study NCT00056407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
Study NCT00056407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
Study NCT00922155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: guide sheath
Description: The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
Study NCT00390117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDKI AT7519
Description: AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
Study NCT00390117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
Study NCT04389112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
Study NCT03289832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crucera-SGS
Description: Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
Study NCT03289832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meriva 500-SF
Description: Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
Study NCT03483805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protalsafe
Description: mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
Study NCT03483805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maize maltodextrin in powder form, to be diluted in water
Study NCT00413920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
Study NCT00413920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
Study NCT00364000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Description: label sevelamer (RenagelR) 800 mg tablets